整合医学对淋巴瘤样丘疹病分型及治疗的探讨

发布时间：2018-06-10 04:15

本文选题：淋巴瘤样丘疹病 + CD　；参考：《医学争鸣》2017年04期

【摘要】：淋巴瘤样丘疹病是一种相对常见的低度恶性皮肤淋巴瘤,与原发性皮肤间变性大细胞淋巴瘤同属于皮肤CD30阳性淋巴细胞增生性疾病。其分型主要有A、B、C、D、E和F型,还有一些特殊的临床及病理分型。但是我们的分型越多就越困惑,因为同样的临床表现与预后,却有着如此截然不同的组织病理学特点。针对淋巴瘤样丘疹病的治疗方法众多,但至今没有证据表明任何一种治疗方案能够减少复发的频率和数量,而且在任何治疗中断后皮损都必然会复发。更重要的是,没有一种治疗能够有效地预防继发淋巴瘤的发生。本文通过回顾淋巴瘤样丘疹病的文献归纳总结出目前最新的组织病理学分类,及对临床预后具有影响的分子和基因,以及可以用来靶向治疗的分子。根据整合医学的思想,制定出一套在现有的技术水平下可以实现的、合理的且易于操作的诊治流程。
[Abstract]:Lymphomatoid papulosis is a relatively common low grade malignant cutaneous lymphoma, which is associated with primary cutaneous anaplastic large cell lymphoma and CD30 positive lymphoproliferative disease. The main types of Astragalus were type E and F, and there were some special clinical and pathological types. But the more we type, the more confused we are, because the same clinical manifestation and prognosis have such distinct histopathological characteristics. There are many treatments for Lymphomatoid papulosis, but there is no evidence that any treatment can reduce the frequency and quantity of recurrence, and the skin lesions will recur after any treatment is interrupted. More importantly, no treatment is effective in preventing secondary lymphoma. In this paper, the latest histopathological classification, molecules and genes that have an effect on clinical prognosis, and molecules that can be used for targeted therapy are summarized by reviewing the literature on lymphomatoid papulosis (Lymphomatoid papulosis). According to the idea of integrated medicine, a set of reasonable and easy to operate diagnosis and treatment flow can be realized under the existing technical level.
【作者单位】：第四军医大学西京皮肤医院;
【基金】：国家自然科学基金面上项目(81372170)
【分类号】：R739.5

【相似文献】